|Page (1) of 1 - 08/01/17||email article||print page|
(August 01, 2017)
LONDON, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (?Verona Pharma), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today that Jan-Anders Karlsson, PhD, CEO of Verona Pharma, is scheduled to present at the 2017 Wedbush PacGrow Healthcare Conference.
An audio webcast of the presentation will be available on the Investors section of the company website, www.veronapharma.com. A replay of the webcast will be made available for 90 days following the presentation.
Event: Wedbush PacGrow Healthcare Conference
Date: August 15, 2017Time: 3:05 PM EDT
About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.
Verona Pharmas product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), and potentially asthma.
For further information, please contact:
|Verona Pharma plc||Tel: +44 (0)20 3283 4200|
|Jan-Anders Karlsson, Chief Executive Officer||[email protected]|
|N+1 Singer (Nominated Adviser and UK Broker)||Tel: +44 (0)20 7496 3000|
|Aubrey Powell / James White|
|FTI Consulting (UK Media and Investor enquiries)||Tel: +44 (0)20 3727 1000|
|Simon Conway / Stephanie Cuthbert / |
|ICR, Inc. (US Media and Investor enquiries)|
|James Heins||Tel: +1 203-682-8251|
|Stephanie Carrington||Tel. +1 646-277-1282|
Related Sites: DMN Newswire , DMN Newswire , HTN - Health Technology Net , HTN - Health Technology Net
Related Newsletter: Tutorial Finder , Tutorial Finder , Review Seeker , Review Seeker , DMN Newswire Newsletter , DMN Newswire Newsletter